IPH 2101 (NN 1975), developed in collaboration with Novo Nordisk A/S, was administered for the first time in patients suffering from multiple myeloma
Approval for phase II trial with IPH 1101 in HCV
In-licensing agreement with Cancer Research Technology on novel TLR agent
Updates on next meetings with analysts and investors
A set of pharmacological data of IPH 1101 was presented at the ASCO annual meeting
Changes in the composition of Innate Pharma's Supervisory Board
Innate Pharma will hold its AGM of Shareholders on June 26, 2007, in Marseilles, France
Number of shares and voting rights, as of April 30, 2007
Turnover of 1.5 million euros for the first quarter of 2007
Two additional clinical trials for IPH 1101, including the first Innate's trial outside oncology
